Expanding The Therapeutic Versatility Of Clascoterone
October 2023
in “
Journal of the American Academy of Dermatology
”
New to Clascoterone? There is a guide in the encyclopedia. Read the guide → 
Studysummary This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
Clascoterone (cortexolone 17α-propionate) cream 1% is a topical treatment for acne vulgaris in patients aged 12 and above, approved in the United States in August 2020. It is believed to work by competing with dihydrotestosterone for androgen receptors located in pilosebaceous units, thereby inhibiting the acnegenic downstream effects of dihydrotestosterone such as lipid synthesis and inflammatory cytokine production in a dose-dependent manner. Its safety profile is similar to placebo regarding systemic antiandrogenic effects. This treatment could potentially be used for other androgen-influenced disorders such as hidradenitis suppurativa and androgenetic alopecia.
